Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OBI-221
- Development stage
- Preclinical
- Lead developer
- OBI Pharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
OBI-221 is a first-in-class bispecific dual-payload antibody-drug conjugate (BsDpADC) developed by OBI Pharmaceuticals. It simultaneously targets the cMET (Hepatocyte Growth Factor Receptor) and HER3 (Human Epidermal Growth Factor Receptor 3) receptors, which are often co-expressed and implicated in resistance to EGFR-targeted therapies. Utilizing the proprietary GlycOBI DUO® platform and HYPrOBI® linker technology, OBI-221 delivers two distinct, synergistic cytotoxic payloads directly to tumor cells. This dual-targeting and dual-payload approach is designed to overcome tumor heterogeneity and bypass common resistance mechanisms in solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer, and gastric cancer.
- Other names
- cMet-HER3-Bispecific Dual-payload ADCcMet-HER-3-Bispecific Dual-payload ADCcMet-HER 3-Bispecific Dual-payload ADC
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on OBI-221.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OBI-221.